title: Pain and continued opioid use in individuals receiving buprenorphine-naloxone for opioid detoxification: secondary analyses from the Clinical Trials Network.
authors.affiliation: Division of Alcohol and Drug Abuse, Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA. potterjs@uthscsa.edu
authors.forename: Jennifer Sharpe
authors.initials: JS
authors.lastname: Potter
authors.forename: Amit
authors.initials: A
authors.lastname: Chakrabarti
authors.forename: Catherine P
authors.initials: CP
authors.lastname: Domier
authors.forename: Maureen P
authors.initials: MP
authors.lastname: Hillhouse
authors.forename: Roger D
authors.initials: RD
authors.lastname: Weiss
authors.forename: Walter
authors.initials: W
authors.lastname: Ling
mesh_terms: D000328:Adult; D000701:Analgesics, Opioid / Q000009:adverse effects / Q000627:therapeutic use*; D002047:Buprenorphine / Q000627:therapeutic use*; D000069479:Buprenorphine, Naloxone Drug Combination; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009270:Naloxone / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000627:therapeutic use; D009293:Opioid-Related Disorders / Q000150:complications / Q000534:rehabilitation*; D010146:Pain / Q000150:complications / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012720:Severity of Illness Index; D013375:Substance Withdrawal Syndrome / Q000534:rehabilitation
chemical_list: D000701:Analgesics, Opioid; D000069479:Buprenorphine, Naloxone Drug Combination; D004338:Drug Combinations; D009292:Narcotic Antagonists; D009270:Naloxone; D002047:Buprenorphine